Galectin Therapeutics (GALT) said Friday its trial evaluating belapectin in cirrhotic portal hypertension patients showed a 48.9% reduction in varices in the per-protocol population for the 2 mg/kg dose group.
In the intent-to-treat population, while the incidence of varices showed a 43.2% reduction, "the composite endpoint did not reach statistical significance," the company said.
The safety profile of belapectin remained favorable, the company said.
Galectin Therapeutics' shares were nearly 30% lower in recent premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。